STUDY TITLE: Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study.
To participate in this trial patients have to be:
Newly diagnosed with Multiple Myeloma.
Ineligible for autologous stem cell transplant.
No prior treatment for multiple myeloma except localised radiotherapy or a short course of steroids.
Multiple Myeloma patients will need to contact their Haematologist to see if they are eligible.
This is a combined Australia/New Zealand study and we have four New Zealand hospitals participating.
Middlemore Hospital, Auckland
Dunedin Hospital, Dunedin
North Shore Hospital, Auckland
Christchurch Hospital, Christchurch
For more information on the trials please follow this link: FRAIL-M FOR TRANSPLANT INELIGIBLE MYELOMA (PHASE I/II) | AMaRC (amarconline.org)